Assessment of hot flashes and clinical correlates in breast cancer patients receiving tamoxifen or third-generation aromatase inhibitors.

被引：0
|
作者：
Morales, L
Neven, P
Cheroutre, E
vande Putte, G
Paridaens, R
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Ctr Ziekenhuis Verplegingswetensch, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：732S / 732S
页数：1
相关论文
共 50 条
  • [1] Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients\
    Morales, L
    Neven, P
    Timmerman, D
    Christiaens, MR
    Vergote, I
    Van Limbergen, E
    Carbonez, A
    Van Huffel, S
    Ameye, L
    Paridaens, R
    ANTI-CANCER DRUGS, 2004, 15 (08) : 753 - 760
  • [2] Third-generation aromatase inhibitors in the treatment of advanced breast cancer
    Jean-Marc A. Nabholtz
    David M. Reese
    Breast Cancer, 2001, 8 (4) : 305 - 309
  • [3] Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors
    不详
    EJC SUPPLEMENTS, 2004, 2 (09): : 19 - 21
  • [4] The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review
    Poole, Raewyn
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (06) : 564 - 572
  • [5] Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors
    Garuti, Giancarlo
    Cellani, Fulvia
    Centinaio, Giovanna
    Montanari, Giuseppe
    Nalli, Giulio
    Luerti, Massimo
    GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 599 - 603
  • [6] THIRD-GENERATION AROMATASE INHIBITORS VS TAMOXIFEN IN THE TREATMENT OF EARLY AND ADVANCED BREAST CANCER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
    von Maltzahn, R.
    Edwards, S. J.
    VALUE IN HEALTH, 2008, 11 (06) : A459 - A459
  • [7] Rivizor - A new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure
    Goss, PE
    Walde, D
    De Coster, R
    Langenaeken, C
    Bruynseels, J
    ONCOLOGY, 1999, 56 (02) : 114 - 121
  • [8] Prospective assessment of loss of grip strength by baseline BMI in breast cancer patients receiving adjuvant aromatase inhibitors or tamoxifen
    Lintermans, A.
    Van Asten, K.
    Wildiers, H.
    Paridaens, R.
    Weltens, C.
    Van Limbergen, E.
    Smeets, A.
    Leunen, K.
    Christiaens, M. R.
    Neven, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S99 - S99
  • [9] Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen
    Lintermans, A.
    Dieudonne, A. S.
    Vanderhaegen, J.
    Henry, N. L.
    Wildiers, H.
    Paridaens, R.
    Christiaens, M. R.
    Smeets, A.
    Leunen, K.
    Neven, P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S159 - S160
  • [10] Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors.
    Sahin, Ugur
    Petekkaya, Ibrahim
    Arslan, Cagatay
    Sarici, Saim Furkan
    Solak, Mustafa
    Keskin, Ozge
    Ozisik, Yavuz Yasin
    Altundag, Kadri
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345